RS-130830
CTS-1027 had been in phase II clinical trials by Conatus Pharmaceuticals (licensed from Roche) for the treatment of HCV infection. However, this study was discontinued due to abnormalities and adverse events in a subset of clinical trial participants. This compound was originally discovered by Roche for the treatment of Arthritis, but there is no development report for this study.
General Information
Update Date：2015-10-14
- Drug Name：
- RS-130830
- Research Code：
- RS-130830; CTS-1027; RO-1130830
- Trade Name：
- MOA：
- Matrix metalloprotease (MMP) inhibitor
- Indication：
- HCV infection; Arthritis
- Status：
- Phase II (Discontinued)
- Company：
- Roche (Originator) , Conatus
- Sales：
- ATC Code：
Chemical Structure
Update Date：2015-10-14
|
Molecular Weight | 425.88 | ||||||||||||
| Formula | C19H20ClNO6S | |||||||||||||
| CAS No. | 193022-04-7 (RS 130830); | |||||||||||||
| Chemical Name | 2H-Pyran-4-carboxamide, 4-[[[4-(4-chlorophenoxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy- | |||||||||||||
| RS 130830 （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||